
|Articles|June 20, 2019
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
Author(s)Adi Diab, MD
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Advertisement
Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab Yields High pCR Rate in Desmoplastic Melanoma
2
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
3
Fecal Microbiota Transplantation Shows Feasibility in Metastatic RCC
4
Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System
5
































